Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Name: Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
Published: 2017
License: Public Domain

Merck Sharp & Dohme LLC · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

gastric neoplasms, gastroesophageal junction adenocarcinoma, programmed cell death-1 (pd1, pd-1), programmed cell death 1 ligand 1 (pdl1, pd-l1), programmed cell death 1 ligand 2 (pdl2, pd-l2), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Related documents